Background: Several studies have suggested that HIF-1α regulates eosinophil activity and induces epithelial inflammation via NF-κB activation in the pathophysiology of asthma. The purpose of this study was to examine the expression of the transcription factors HIF-1α and nuclear HIF in mononuclear cells obtained from peripheral blood samples of healthy pediatric patients, asthmatic patients, and asthmatic exacerbations, regardless of disease severity.Methods: HIF-1 levels were measured using immunocytochemistry in 133 patients aged 6 to 17 years in this cross-sectional and comparative study. A microscope was used to examine glass slides, and positive cells were counted in four fields per slide using an image analyzer.Results: HIF-1α and nuclear HIF levels were significantly higher in asthma patients and even higher in patients experiencing asthma attacks (p<0.0001, 95% CI). There was no significant difference in the percentage of HIF-1α expression between groups with intermittent asthma and those with mild persistent asthma, nor between patients with asthma and those experiencing asthma exacerbations.Conclusions: When compared to healthy individuals, the expression of nuclear HIF and HIF-1α is increased in peripheral mononuclear cells in asthma patients and even more so in asthma exacerbations. This suggests that HIF-1α is important in the pathogenesis of this disease.
26 October 2026 in Immunity, Inflammation and Disease
Background: Allergen immunotherapy (AIT) may modify allergic respiratory disease, but its association with progression and remission in routine practice remains uncertain. Materials and Methods: We emulated a target trial in a single‐center retrospective cohort at AlergiaMx, Mexico City, using data from 2020 to 2025. We compared sublingual allergen immunotherapy initiation within a 14‐day grace period with non‐initiation among AIT‐eligible patients. Follow‐up extended up to 36 months, and propensity‐score overlap weighting addressed baseline confounding. Results: Among 2,713 patients, 1,971 initiated AIT and 742 did not. Weighted disease worsening was 46.3% versus 63.6% (relative risk [RR] 0.73, 95% confidence interval [CI] 0.65–0.82), and sustained progression was 8.4% versus 17.0% (RR 0.49, 95% CI 0.35–0.69). At 36 months, clinical remission was 47.0% versus 18.3% (RR 2.57, 95% CI 1.93–3.43), and treatment‐associated remission was 31.7% versus 5.8% (RR 5.44, 95% CI 3.23–9.16). Longitudinal differences favored AIT for asthma control, quality of life, and fractional exhaled nitric oxide. Discussion: AIT initiation was associated with less worsening, greater remission, and favorable clinical and inflammatory trajectories over 36 months. These observational findings do not establish a causal disease‐modifying effect; residual confounding and differential follow‐up remain possible.
15 February 2026 in The Clinical Respiratory Journal
Background: Children with asthma living in highly polluted megacities are at increased risk of poor asthma control and airway inflammation. Breastfeeding has immunomodulatory effects, but its potential to buffer pollution‐related inflammation remains understudied. Objective: To evaluate whether breastfeeding duration is associated with asthma control and airway eosinophilic inflammation (FeNO), and whether it modifies the impact of urban air pollution in children with asthma living in Mexico City. Methods: We conducted a multicenter retrospective study (2022–2025) including children aged 6–17 years with physician‐diagnosed asthma. Asthma control (ACT), airway inflammation (FeNO, NIOX VERO), breastfeeding duration (0–12 months), and borough‐level pollution categories (high/medium/low) were evaluated. Multivariable logistic and linear regression models assessed associations and breastfeeding × pollution interactions. Results: A total of 162 children were included (mean age 10.8 years; 51.2% female). Breastfeeding ≥ 6 months was associated with better asthma control (ACT ≥ 20: OR 2.1; 95% CI 1.3–3.5) and significantly lower FeNO (β −0.24; p < 0.01). High‐pollution residence was linked to lower ACT scores and higher FeNO (both p < 0.01). A significant interaction indicated that breastfeeding ≥ 6 months attenuated the detrimental effect of pollution on airway inflammation and asthma control ( p for interaction < 0.05). Conclusions: Prolonged breastfeeding was independently associated with improved asthma control and reduced airway eosinophilic inflammation, partially mitigating the respiratory burden of chronic pollution exposure. Clinical Implications: Breastfeeding may serve as an accessible, low‐cost protective strategy for children with asthma living in polluted urban environments, supporting its integration into respiratory health policies and early‐life preventive care.